FDA Approves RYBELSUS ® as a First-Line Option for Adults with Type-2 Diabetes
Dr. Aaron King, Family Medicine and Diabetes Specialist at MedFirst Primary Care, a Baptist Medical Center affiliate, discusses the recent FDA approval of a label update for Novo Nordisk’s RYBELSUS ® (semaglutide) as a first-line option for adults living with type 2 diabetes. He is joined by Beto who is living with type 2 diabetes and shares his experience with being prescribed RYBELSUS ® to manage his condition, along with diet and exercise.
Dr. Aaron King is a Family Medicine and Diabetes Specialist at MedFirst Primary Care, a Baptist Medical Center affiliate. Dr. King graduated from the University of Texas with a B.S. in Microbiology and top of his class at Texas A&M Medical School, while on a scholarship with the United States Navy through the HPSP program. After his USN commission, Dr. King became ABFM certified in Family Medicine after his residency at Navy Hospital Pensacola. He has received multiple awards including Chief Resident and Resident Instructor of the Year and has served as an active-duty family medicine doctor as the Senior Medical Officer in Diego Garcia, as well as an instructor at the Interservice Physician Assistant Program. Following the Navy, Dr. King continued his family medicine career while serving as a consultant and speaker for multiple pharmaceutical companies focused on the diabetes space. He has also published several peer reviewed original research articles, literature review articles and real-world clinical research articles.
